================================================================================
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
------------------------------------
FORM 8-K
Current Report Filed Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report
(Date of earliest event reported): September 13, 1999
ZONAGEN, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-21198 76-0233274
(State or other jurisdiction of (Commission File Number) (I.R.S. Employer Identification No.)
incorporation or organization)
2408 Timberloch Place, Suite B-4
The Woodlands, Texas 77380
(Address of principal
executive offices
and zip code)
(281) 719-3400
(Registrant's telephone number,
including area code)
------------------------------------
================================================================================
Item 5. Other Events
On September 13, 1999, Zonagen, Inc. issued a press release announcing
the focus of its resources on its lead product candidates - Vasomax(R) and
Vasofem(TM). The action will result in the dismissal of 15 employees,
representing a reduction of approximately one-third of the Company's work force.
The press release is filed as an exhibit to this Current Report on Form
8-K and is incorporated by reference herein.
Item 7. Exhibits
Exhibit 99.1 -- Press Release
-2-
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
ZONAGEN, INC.
Date: September 14, 1999
By: /s/ F. Scott Reding
---------------------------------
F. Scott Reding
Chief Financial Officer
-3-